fda-consultant-specialist

FDA Consultant Specialist

FDA regulatory consulting for medical device manufacturers covering submission pathways, the Quality Management System Regulation (QMSR, 21 CFR Part 820 — formerly the QSR), HIPAA compliance, and device cybersecurity requirements.

Table of Contents

• FDA Pathway Selection
• 510(k) Submission Process
• QMSR Compliance (formerly QSR)
• HIPAA for Medical Devices
• Device Cybersecurity
• Resources

---

FDA Pathway Selection

Determine the appropriate FDA regulatory pathway based on device classification and predicate availability.

Decision Framework

Predicate device exists?
├── YES → Substantially equivalent?
│   ├── YES → 510(k) Pathway
│   │   ├── No design changes → Abbreviated 510(k)
│   │   ├── Manufacturing only → Special 510(k)
│   │   └── Design/performance → Traditional 510(k)
│   └── NO → PMA or De Novo
└── NO → Novel device?
    ├── Low-to-moderate risk → De Novo
    └── High risk (Class III) → PMA

Pathway Comparison

Pathway	When to Use	Timeline	User Fee (FY2024)
510(k) Traditional	Predicate exists, design changes	90 days	$21,760 (FY2024)
510(k) Special	Manufacturing changes only	30 days	$21,760 (FY2024)
510(k) Abbreviated	Guidance/standard conformance	30 days	$21,760 (FY2024)
De Novo	Novel, low-moderate risk	150 days	$134,676 (FY2024)
PMA	Class III, no predicate	180+ days	$425,000+ (FY2024)

User fees are set annually under MDUFA. Verify current-fiscal-year fees at fda.gov (MDUFA user fee schedule) before budgeting; small-business rates differ.

Pre-Submission Strategy

1. Identify product code and classification
2. Search 510(k) database for predicates
3. Assess substantial equivalence feasibility
4. Prepare Q-Sub questions for FDA
5. Schedule Pre-Sub meeting if needed

Reference: See fda_submission_guide.md for pathway decision matrices and submission requirements.

---

510(k) Submission Process

Workflow

Phase 1: Planning
├── Step 1: Identify predicate device(s)
├── Step 2: Compare intended use and technology
├── Step 3: Determine testing requirements
└── Checkpoint: SE argument feasible?

Phase 2: Preparation
├── Step 4: Complete performance testing
├── Step 5: Prepare device description
├── Step 6: Document SE comparison
├── Step 7: Finalize labeling
└── Checkpoint: All required sections complete?

Phase 3: Submission
├── Step 8: Assemble submission package
├── Step 9: Submit via eSTAR
├── Step 10: Track acknowledgment
└── Checkpoint: Submission accepted?

Phase 4: Review
├── Step 11: Monitor review status
├── Step 12: Respond to AI requests
├── Step 13: Receive decision
└── Verification: SE letter received?

Required Sections (21 CFR 807.87)

Section	Content
Cover Letter	Submission type, device ID, contact info
Form 3514	CDRH premarket review cover sheet
Device Description	Physical description, principles of operation
Indications for Use	Form 3881, patient population, use environment
SE Comparison	Side-by-side comparison with predicate
Performance Testing	Bench, biocompatibility, electrical safety
Software Documentation	Level of concern, hazard analysis (IEC 62304)
Labeling	IFU, package labels, warnings
510(k) Summary	Public summary of submission

Common RTA Issues

Issue	Prevention
Missing user fee	Verify payment before submission
Incomplete Form 3514	Review all fields, ensure signature
No predicate identified	Confirm K-number in FDA database
Inadequate SE comparison	Address all technological characteristics

---

QMSR Compliance (formerly QSR)

Quality Management System Regulation (QMSR) requirements for medical device manufacturers under 21 CFR Part 820.

QMSR transition (effective 2026-02-02): FDA's QMSR final rule (89 FR 7496) amended 21 CFR Part 820 to incorporate ISO 13485:2016 by reference and removed the legacy QSR subsection structure (820.20–820.198). Those subsection numbers are historical and no longer exist in the CFR; the corresponding requirements now flow from ISO 13485:2016 clauses plus the retained/renumbered sections 820.10 (requirements, incl. the ISO 13485 incorporation), 820.35 (records), and 820.45 (device labeling and packaging controls). 21 CFR Parts 801, 803, 806, and 830 are unchanged. Legacy QSR numbers below are kept only as a familiar index, each mapped to its current ISO 13485 clause.

Key Quality Subsystems (legacy QSR index → current ISO 13485:2016 clause)

Legacy QSR Section (historical, pre-2026)	Title	Current authority under QMSR	Focus
820.20	Management Responsibility	ISO 13485 §5.1, 5.5, 5.6	Quality policy, org structure, management review
820.30	Design Controls	ISO 13485 §7.3	Input, output, review, verification, validation
820.40	Document Controls	ISO 13485 §4.2.4	Approval, distribution, change control
820.50	Purchasing Controls	ISO 13485 §7.4	Supplier qualification, purchasing data
820.70	Production Controls	ISO 13485 §6.3, 6.4, 7.5	Process validation, environmental controls
820.100	CAPA	ISO 13485 §8.5.2, 8.5.3	Root cause analysis, corrective actions
820.181	Device Master Record	ISO 13485 §4.2.3 (medical device file) + 21 CFR 820.35	Specifications, procedures, acceptance criteria

Design Controls Workflow (ISO 13485 §7.3; legacy QSR 820.30)

Step 1: Design Input
└── Capture user needs, intended use, regulatory requirements
    Verification: Inputs reviewed and approved?

Step 2: Design Output
└── Create specifications, drawings, software architecture
    Verification: Outputs traceable to inputs?

Step 3: Design Review
└── Conduct reviews at each phase milestone
    Verification: Review records with signatures?

Step 4: Design Verification
└── Perform testing against specifications
    Verification: All tests pass acceptance criteria?

Step 5: Design Validation
└── Confirm device meets user needs in actual use conditions
    Verification: Validation report approved?

Step 6: Design Transfer
└── Release to production with DMR complete
    Verification: Transfer checklist complete?

CAPA Process (ISO 13485 §8.5.2/8.5.3; legacy QSR 820.100)

1. Identify: Document nonconformity or potential problem
2. Investigate: Perform root cause analysis (5 Whys, Fishbone)
3. Plan: Define corrective/preventive actions
4. Implement: Execute actions, update documentation
5. Verify: Confirm implementation complete
6. Effectiveness: Monitor for recurrence (30-90 days)
7. Close: Management approval and closure

Reference: See qsr_compliance_requirements.md for the historical QSR structure with full QMSR/ISO 13485:2016 clause mapping.

---

HIPAA for Medical Devices

HIPAA requirements for devices that create, store, transmit, or access Protected Health Information (PHI).

Applicability

Device Type	HIPAA Applies
Standalone diagnostic (no data transmission)	No
Connected device transmitting patient data	Yes
Device with EHR integration	Yes
SaMD storing patient information	Yes
Wellness app (no diagnosis)	Only if stores PHI

Required Safeguards

Administrative (§164.308)
├── Security officer designation
├── Risk analysis and management
├── Workforce training
├── Incident response procedures
└── Business associate agreements

Physical (§164.310)
├── Facility access controls
├── Workstation security
└── Device disposal procedures

Technical (§164.312)
├── Access control (unique IDs, auto-logoff)
├── Audit controls (logging)
├── Integrity controls (checksums, hashes)
├── Authentication (MFA recommended)
└── Transmission security (TLS 1.2+)

Risk Assessment Steps

1. Inventory all systems handling ePHI
2. Document data flows (collection, storage, transmission)
3. Identify threats and vulnerabilities
4. Assess likelihood and impact
5. Determine risk levels
6. Implement controls
7. Document residual risk

Reference: See hipaa_compliance_framework.md for implementation checklists and BAA templates.

---

Device Cybersecurity

FDA cybersecurity requirements for connected medical devices.

Premarket Requirements

Element	Description
Threat Model	STRIDE analysis, attack trees, trust boundaries
Security Controls	Authentication, encryption, access control
SBOM	Software Bill of Materials (CycloneDX or SPDX)
Security Testing	Penetration testing, vulnerability scanning
Vulnerability Plan	Disclosure process, patch management

Device Tier Classification

Tier 1 (Higher Risk):

• Connects to network/internet
• Cybersecurity incident could cause patient harm

Tier 2 (Standard Risk):

• All other connected devices

Postmarket Obligations

1. Monitor NVD and ICS-CERT for vulnerabilities
2. Assess applicability to device components
3. Develop and test patches
4. Communicate with customers
5. Report to FDA per guidance

Coordinated Vulnerability Disclosure

Researcher Report
    ↓
Acknowledgment (48 hours)
    ↓
Initial Assessment (5 days)
    ↓
Fix Development
    ↓
Coordinated Public Disclosure

Reference: See device_cybersecurity_guidance.md for SBOM format examples and threat modeling templates.

---

Resources

scripts/

Script	Purpose
fda_submission_tracker.py	Track 510(

---

Content truncated.